Bright Minds Biosciences (DRUG) Operating Leases (2022 - 2025)

For the quarter ending Q3 2025, Operating Leases rose 3.31% year-over-year to $29973.0, compared with a TTM value of $29973.0 through Sep 2025, up 3.31%, and an annual FY2025 reading of $29973.0, up 3.31% over the prior year.

Bright Minds Biosciences (DRUG) has disclosed Operating Leases for 3 consecutive years, with $29973.0 as the latest value for Q3 2025.

  • Operating Leases reached $29973.0 in Q3 2025 per DRUG's latest filing, up from $29011.3 in the prior quarter.
  • Across five years, Operating Leases topped out at $107276.2 in Q3 2022 and bottomed at $29011.3 in Q3 2024.
  • Average Operating Leases over 3 years is $55420.2, with a median of $29973.0 recorded in 2025.
  • The widest YoY moves for Operating Leases: up 3.31% in 2025, down 3.31% in 2025.
  • Bright Minds Biosciences' Operating Leases stood at $107276.2 in 2022, then tumbled by 72.96% to $29011.3 in 2024, then increased by 3.31% to $29973.0 in 2025.
  • Per Business Quant, the three most recent readings for DRUG's Operating Leases are $29973.0 (Q3 2025), $29011.3 (Q3 2024), and $107276.2 (Q3 2022).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 605.66 Bn 605.66 Bn -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn
8 Evaxion A 65.12 Bn 65.10 Bn -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn
10 Bright Minds Biosciences 464.72 Mn 405.19 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 12,006.89
Sep 30, 2025 29,972.97
Jun 30, 2025 45,353.86
Mar 31, 2025 61,918.24
Dec 31, 2024 130,809.26
Sep 30, 2024 29,011.32
Dec 31, 2023 40,078.46
Jun 30, 2023 10,434.25
Mar 31, 2023 25,691.13
Dec 31, 2022 40,197.46
Sep 30, 2022 107,276.23